top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

CV

Research Summary

As a health equity researcher and pharmacoepidemiologist, I am interested in the influence of healthcare services, especially medications, on population health. For instance, are certain populations underusing medications or using them unsafely? I use an interdisciplinary approach to identify how structural determinants—macro-level systems, institutions, and policies—impact healthcare use, especially medications in diverse populations. 

 

My research focuses on: â€‹

  • inequities in access to care & health outcomes among immigrants

  • racial/ethnic and socioeconomic inequities in cancer care

  • drug utilization patterns among diverse populations

  • the role of pharmacy systems in determining access to medications

​

For example, I co-authored multiple highly publicized studies examining drug utilization patterns, including the prevalence of drug-drug interactions, among children and adolescents in the US (in Pediatrics & JAMA Pediatr.). Recently, I published a study examining medications included and released from the FDA’s Risk Evaluation and Mitigation Strategy program (in JAMA). I have also published multiple studies examining disparities in access to pharmacies, including the rate of closures (in JAMA Intern. Med.), in underserved communities. My dissertation research focused on immigration status and its association with the prevalence and management of cardiovascular disease risk factors (in Am. J. Public Health & CIRC-CARDIOVASC QUAL.). Immigration status may be a critical yet overlooked factor influencing inequities because noncitizens experience significant barriers to legal and social protection, including inadequate healthcare access.  My unique research perspective has been of considerable interest and has garnered funding from the US National Heart, Lung, and Blood Institute and the Robert Wood Johnson Foundation.

​

Skills

  • A trained pharmacoepidemiologist with expertise in health services, drug utilization, and population health research

  • Extensive experience working with large secondary data sources including administrative claims, clinical provider registries, multi-national cross-sectional surveys, and population-based cohorts

  • Skilled in statistical analysis and software (e.g., R & Stata)

  • Proficient in Geographic Information Systems and related software (e.g., ArcGIS)

  • Languages: English (native fluency), Spanish (heritage speaker, advanced professional)

Research Experience

2023-Present

University of California, Berkeley School of Public Health

Assistant Professor, Division of Health Policy & Management

​

2021-2023

Flatiron Health

Sr. Health Equity Scientist (2023)

Quantitative Scientist (2021-2023)​

​

2020-2023

University of Southern California School of Pharmacy

Postdoctoral Research Fellow, Program of Medicines & Public Health

​

2019-2020

Université Libre de Bruxelles Ecole de Santé Publique

Visiting Scholar, Center of International Health Policies & Systems

​

2018-2020

University of Illinois at Chicago College of Medicine

Predoctoral Research Fellow, Institute for Minority Health Research

​

2015-2018

University of Illinois at Chicago College of Pharmacy

Research Assistant, Department of Pharmacy Systems, Outcomes, & Policy

Education

2020

PhD, University of Illinois at Chicago

Pharmacoepidemiology & Pharmaceutical Policy

​

2017

MS, University of Illinois at Chicago

Health Policy & Administration (Global Health)

​

2013

BA, Saint Louis University

Economics

Select Publications

Pubmed Bibliography Lists All Peer-Reviewed Publications

​

  1. Guadamuz JS, Wang X, Royce TJ, Calip GS. (2023). Racial and Socioeconomic Disparities in Telemedicine Use Among US Patients Initiating Cancer Treatment During the COVID-19 Pandemic. JCO Oncol. Pract.

  2. Guadamuz JS, Wang X, Ryals CA, Miksad R, Snider J, Walters J, and Calip GS. (2023). Socioeconomic Status and Inequities in Treatment Initiation and Survival Among Patients with Cancer, 2011-2022. JNCI Cancer Spectr.

  3. Pittel H, Calip GS, Altomare I, Ryals CA, Guadamuz JS. (2023). Racial and Ethnic Inequities in US Oncology Clinical Trial Participation from 2017 to 2022. JAMA Netw. Open.

  4. Guadamuz JS, Qato DM. (2023). Citizenship Status and Cost-Related Nonadherence in the United States, 2017-2021. Health Serv Res.

  5. Guadamuz JS, Shooshtari A, Qato DM. (2022). Global, Regional, and National Trends in Statin Utilization in High-Income and Low- and Middle-Income Countries, 2015-2020. BMJ Open.

  6. ​Guadamuz JS, Durazo-Arvizu RA, Flores-Morales J, Qato DM. (2022). Citizenship Status and Mortality Among Young Latino Adults in the U.S., 1998‒2015. Am. J. Prev. Med.

  7. Guadamuz JS, Alexander GC, Kanter GP, et al. (2021). Access to Pharmacies and Pharmacy Services in New York City, Los Angeles, Chicago, and Houston, 2015-2020. J Am Pharm Assoc.

  8. Guadamuz JS, Wilder JR, Mouslim MC, et al. (2021). Fewer Pharmacies in Black and Hispanic/Latino Neighborhoods Compared with White or Diverse Neighborhoods, 2007-15. Health Aff.

  9. Guadamuz JS, Kapoor K, Lazo-Elizondo M, et al. (2021). Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanic/Latinos and South Asian Living in the United States. Curr Atheroscler Rep.

  10. Guadamuz JS, Qato DM, Alexander GC. (2020) Use of Risk Evaluation and Mitigation Strategies by the U.S. Food and Drug Administration, 2008-2019. JAMA.​​

  11. Guadamuz JS, Durazo-Arvizu RA, Daviglus ML, et al. (2020). Immigration Status and Disparities in the Treatment of Cardiovascular Disease Risk Factors in the Hispanic Community Health Study/Study of Latinos (Visit 2, 2014–2017). Am. J. Public Health.

  12. Guadamuz JS, Durazo-Arvizu RA, Daviglus ML, et al. (2020). Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Adults in the United States, 2011– 2016. CIRC-CARDIOVASC QUAL.

  13. Guadamuz JS, Alexander GC, Zenk S, Qato DM. (2019). Assessment of Pharmacy Closures in the United States From 2009 Through 2015. JAMA Intern. Med.

  14. Guadamuz JS, Alexander GC, Chaudhri T, et al. (2019). Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017. JAMA Netw. Open.

  15. Guadamuz JS, Ozenberger K, Qato DM, et al. (2019). Mediation Analyses of Socioeconomic Factors Determining Racial Differences in the Treatment of Elderly Diffuse Large B-cell Lymphoma. Medicine.

​

​

bottom of page